Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies. As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans. Part of Utrecht Science Park Bilthoven
| Website | https://www.intravacc.nl |
| Revenue | $28.7 million |
| Employees | 44 (42 on RocketReach) |
| Founded | 2013 |
| Address | Antonie van Leeuwenhoeklaan 9, Bilthoven, Utrecht 3721 MA, NL |
| Phone | +31 30 792 0300 |
| Technologies |
JavaScript
,
HTML
,
PHP
+24 more
(view full list)
|
| Industry | Biotechnology Research |
| Web Rank | 1 Million |
| Keywords | Therapeutic Vaccines, Vaccine Development, Vaccine Technology, Vaccine Production, Vaccine Manufacturing, Biotechnology, Medical Research, Pharmaceutical Research, Pharmaceutical Manufacturing, Immunology, Pharmaceutical, Biologics, Preclinical Development, Drug Manufacturing, Clinical Stage, Drug Development, Clinical Trials, Health Technology, Life Sciences, Bioprocessing |
| Competitors | Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Baxter International Inc., Moderna Therapeutics, Novavax +40 more (view full list) |
Looking for a particular Intravacc employee's phone or email?
The Intravacc annual revenue was $28.7 million in 2026.
Nathalie James is the CFO of Intravacc.
42 people are employed at Intravacc.
Intravacc is based in Bilthoven, Utrecht.